Dare Bioscience Inc. Common Stock (DARE)
Stock · NASDAQ · Health Care
$0.7135as of 10/16/2026
Price chart
Active signals
DARE Signal Track Record
How signals performed across all stocks →What DARE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -8.7% | 24% | September 24, 2026 |
| Bollinger Band Breakdown | 26 | -0.9% | 42% | August 14, 2026 |
| Bollinger Band Breakout | 19 | -8.4% | 32% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -11.8% | 23% | June 25, 2026 |
| Any 20-session window (baseline) | -4.3% | 32% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topic…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- www.darebioscience.com/
Fundamentals
- 1-day range
- $0.7126$0.7397
- Market cap
- $19.92M
- P/E (trailing)
- —
- P/E (forward)
- -1.75
- EPS (trailing)
- $-0.79
- Dividend yield
- —
- Beta
- 1.14
- Avg. volume
- 522.6K
- Dividend pay date
- July 20, 2017
How Dare Bioscience Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Dare Bioscience Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DAREDare Bioscience Inc. Common Stock$0.725▼ 2.03%Market cap $19.92MP/E —$0.69$3.78
- GRDXGridAI Technologies Corp. Common Stock$4.22▼ 5.38%Market cap $19.91MP/E —$1.87$6.93
- CELUCelularity Inc. Class A Common Stock$1.25▼ 6.02%Market cap $19.77MP/E —$0.5601$2.55
- RKTORocket One Inc. Common Stock$0.507▼ 5.59%Market cap $19.75MP/E —$0.51$2.45
- CLRBCellectar Biosciences Inc. Common Stock$1.14▼ 4.20%Market cap $20.14MP/E —$1.15$5.07
- NXTCNextCure Inc. Common Stock$6.24▼ 9.30%Market cap $20.19MP/E —$1.55$15.74
- HOWLWerewolf Therapeutics Inc. Common Stock$0.98▼ 1.71%Market cap $19.58MP/E —$0.27$2.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DARE Dare Bioscience Inc. Common Stock | $19.92M | — | $0.725 | ▼ 2.03% | $0.69$3.78 |
| GRDX GridAI Technologies Corp. Common Stock | $19.91M | — | $4.22 | ▼ 5.38% | $1.87$6.93 |
| CELU Celularity Inc. Class A Common Stock | $19.77M | — | $1.25 | ▼ 6.02% | $0.5601$2.55 |
| RKTO Rocket One Inc. Common Stock | $19.75M | — | $0.507 | ▼ 5.59% | $0.51$2.45 |
| CLRB Cellectar Biosciences Inc. Common Stock | $20.14M | — | $1.14 | ▼ 4.20% | $1.15$5.07 |
| NXTC NextCure Inc. Common Stock | $20.19M | — | $6.24 | ▼ 9.30% | $1.55$15.74 |
| HOWL Werewolf Therapeutics Inc. Common Stock | $19.58M | — | $0.98 | ▼ 1.71% | $0.27$2.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific MeetingYahoo · 10/8/2026
- Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11Benzinga · 10/8/2026
- Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain ComplianceBenzinga · 10/2/2026
- Dare Bioscience stock rises after receiving HPV treatment patentYahoo · 9/28/2026
- Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV InfectionYahoo · 9/28/2026
- Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical PathologiesBenzinga · 9/28/2026
- Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral SildenafilYahoo · 9/14/2026
- Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral DoseBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Gregory W. Matz · June 30, 2026 · Grant30.8K
- Robin Joan Steele · June 30, 2026 · Grant26.5K
- William H. Rastetter · June 30, 2026 · Grant38.9K
- Jessica D. Grossman · June 30, 2026 · Grant26.1K
- Susan L. Kelley · June 30, 2026 · Grant23.7K
- Gregory W. Matz · June 11, 2026 · Grant10.0K
- Jessica D. Grossman · June 11, 2026 · Grant10.0K
- Robin Joan Steele · June 11, 2026 · Grant10.0K
- Susan L. Kelley · June 11, 2026 · Grant10.0K
- William H. Rastetter · June 11, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 955.9K
- Total value held
- $1.72M
- Institutional holders
- 23
- Unknown462.3K
- Unknown177.8K
- Unknown91.4K
- Unknown43.4K
- Unknown23.5K
- Unknown22.3K
- Unknown17.1K
- Unknown17.0K
- Unknown15.4K
- Unknown15.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
DARE Receives New Patents for HPV and Cervical Treatments
Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.
DARE Receives New Patents for HPV and Cervical Treatments. Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.